UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 47

Sortiert nach

P253 ARV-471, a PROTAC® estrogen receptor (ER) degrader in advanced ER+/human epidermal growth factor receptor 2 (HER2)- breast cancer: phase 2 expansion (VERITAC) of a phase 1/2 study

Breast (Edinburgh), 2023-04, Vol.68, p.S116-S116

2023

Link zum Volltext

Verfügbarkeit prüfen

Antitumor activity of sorafenib in FLT3-driven leukemic cells

Leukemia, 2007-03, Vol.21 (3), p.439-445

2007

Link zum Volltext

Verfügbarkeit prüfen

210 A phase 1 study of KTN3379, a human anti-ErbB3 monoclonal antibody in patients with advanced cancers

European journal of cancer (1990), 2014-11, Vol.50, p.71-71

2014

Link zum Volltext

Verfügbarkeit prüfen

202 KTN0158, a humanized anti-KIT monoclonal antibody, demonstrates antitumor activity in dogs with mast cell tumors

European journal of cancer (1990), 2015-09, Vol.51, p.S27-S27

2015

Link zum Volltext

Verfügbarkeit prüfen

A conserved family of cellular genes related to the baculovirus iap gene and encoding apoptosis inhibitors

The EMBO journal, 1996-06, Vol.15 (11), p.2685-2694

1996

Link zum Volltext

Verfügbarkeit prüfen

A phase 1 study of OSI-930 in combination with erlotinib in patients with advanced solid tumours

European journal of cancer (1990), 2013-03, Vol.49 (4), p.782-789

2013

Link zum Volltext

Verfügbarkeit prüfen

1407P Real-world outcomes in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and tumors with androgen receptor (AR) 878/875 mutations

Annals of oncology, 2022-09, Vol.33, p.S1188

2022

Link zum Volltext

Verfügbarkeit prüfen

1803P Phase I/II study of bavdegalutamide, a PROTAC androgen receptor (AR) degrader in metastatic castration-resistant prostate cancer (mCRPC): Radiographic progression-free survival (rPFS) in patients (pts) with AR ligand-binding domain (LBD) mutations

Annals of oncology, 2023-10, Vol.34, p.S973-S974

2023

Link zum Volltext

Verfügbarkeit prüfen

390P Vepdegestrant, a proteolysis targeting chimera (PROTAC) estrogen receptor (ER) degrader, in ER+/human epidermal growth factor receptor 2 (HER2)- advanced breast cancer: Update of dose escalation results from a phase I/II trial

Annals of oncology, 2023-10, Vol.34, p.S344-S344

2023

Link zum Volltext

Verfügbarkeit prüfen

Induction of Nuclear Factor κB by the CD30 Receptor Is Mediated by TRAF1 and TRAF2

Molecular and cellular biology, 1997-03, Vol.17 (3), p.1535-1542

1997

Link zum Volltext

Verfügbarkeit prüfen

Transcriptional repression of the c-fos gene by YY1 is mediated by a direct interaction with ATF/CREB

Journal of Virology, 1995-07, Vol.69 (7), p.4323-4330

1995

Link zum Volltext

Verfügbarkeit prüfen

Tumor necrosis factor receptor-associated factors (TRAFs)--a family of adapter proteins that regulates life and death

Genes & development, 1998-09, Vol.12 (18), p.2821-2830

1998

Link zum Volltext

Verfügbarkeit prüfen

CD30 Contains Two Binding Sites with Different Specificities for Members of the Tumor Necrosis Factor Receptor-associated Factor Family of Signal Transducing Proteins

The Journal of biological chemistry, 1996-05, Vol.271 (22), p.12852-12858

1996

Link zum Volltext

Verfügbarkeit prüfen

D100 CDX-0159, AN ANTI-KIT MONOCLONAL ANTIBODY, AS A MODULATOR OF MAST CELL-RELATED DISEASES

Annals of allergy, asthma, & immunology, 2019-11, Vol.123 (5), p.S14-S14

2019

Link zum Volltext

Verfügbarkeit prüfen

256TiP TACTIVE-E: Phase Ib study of ARV-471, a PROteolysis TArgeting Chimera (PROTAC) estrogen receptor (ER) degrader, in combination with everolimus in ER+/human epidermal growth factor receptor 2 (HER2)- advanced breast cancer

ESMO open, 2023-05, Vol.8 (1), p.101444, Article 101444

2023

Link zum Volltext

Verfügbarkeit prüfen

Translocation of TRAF Proteins Regulates Apoptotic Threshold of Cells

Biochemical and biophysical research communications, 2000-06, Vol.272 (3), p.936-945

2000

Link zum Volltext

Verfügbarkeit prüfen

205P VERITAC update: Phase II study of ARV-471, a PROteolysis TArgeting Chimera (PROTAC) estrogen receptor (ER) degrader in ER+/human epidermal growth factor receptor 2 (HER2)- advanced breast cancer

ESMO open, 2023-05, Vol.8 (1), p.101394, Article 101394

2023

Link zum Volltext

Verfügbarkeit prüfen

154TiP TACTIVE-N: Open-label, randomized, noncomparative neoadjuvant phase 2 study of ARV-471, a PROteolysis TArgeting Chimera (PROTAC) estrogen receptor (ER) degrader, or anastrozole in postmenopausal women with ER+/human epidermal growth factor receptor 2 (HER2)- localized breast cancer

ESMO open, 2023-05, Vol.8 (1), p.101493, Article 101493

2023

Link zum Volltext

Verfügbarkeit prüfen

49 POSTER Analyses of pharmacodynamic (PD) assessments collected during expanded cohorts (EC) of a phase I trial with OSI-930, a multi-targeted oral tyrosine kinase inhibitor (TKI)

European journal of cancer supplements, 2008, Vol.6 (12), p.19-19

2008

Link zum Volltext

Verfügbarkeit prüfen

Identification of a novel E1A response element in the mouse c-fos promoter

Journal of Virology, 1995-04, Vol.69 (4), p.2333-2340

1995

Link zum Volltext

Verfügbarkeit prüfen

Phase I study of OSI-906, dual tyrosine kinase inhibitor of insulin-like growth factor-1 receptor (IGF-1R) and insulin receptor (IR) in combination with erlotinib (E) in patients with advanced solid tumors

Journal of clinical oncology, 2011-05, Vol.29 (15_suppl), p.3098-3098

2011

Link zum Volltext

Verfügbarkeit prüfen

Induction of AP-1 DNA-binding activity and c-fos mRNA by the adenovirus 243R E1A protein and cyclic AMP requires domains necessary for transformation

Journal of Virology, 1992-10, Vol.66 (10), p.5849-5859

1992

Link zum Volltext

Verfügbarkeit prüfen

Phase I study of intermittent dosing of OSI-906, a dual tyrosine kinase inhibitor of insulin-like growth factor-1 receptor (IGF- 1R) and insulin receptor (IR) in patients with advanced solid tumors

Journal of clinical oncology, 2010-05, Vol.28 (15_suppl), p.2530-2530

2010

Link zum Volltext

Verfügbarkeit prüfen

A dose escalation (DE), pharmacokinetic (PK), and pharmacodynamic (PD) study of OSI-930 and erlotinib (E) in patients (pts) with advanced solid tumors

Journal of clinical oncology, 2009-05, Vol.27 (15_suppl), p.3550-3550

2009

Link zum Volltext

Verfügbarkeit prüfen

First-in-human phase I study exploring three schedules of OSI-027, a novel small molecule TORC1/TORC2 inhibitor, in patients with advanced solid tumors and lymphoma

Journal of clinical oncology, 2010-05, Vol.28 (15_suppl), p.3006-3006

2010

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 47

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(46)
Mit Volltextzugriff
(47)

Publikationsform

Artikel
(46)
Tagungsberichte
(1)

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(19)
Life Sciences & Biomedicine
(16)
Humans
(13)
Animals
(7)
Cell Line
(7)
Female
(6)
Mice
(6)
Oncology
(6)
Base Sequence
(5)
Biological And Medical Sciences
(5)
Male
(5)
Molecular Sequence Data
(5)
Adult
(4)
Biochemistry & Molecular Biology
(4)
Hematology, Oncology And Palliative Medicine
(4)
Proteins - Genetics
(4)
Aged
(3)
Chemistry
(3)
Diet
(3)
Dose-Response Relationship, Drug
(3)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

P253 ARV-471, a PROTAC® estrogen receptor (ER) degrader in advanced ER+/human epidermal growth factor receptor 2 (HER2)- breast cancer: phase 2 expansion (VERITAC) of a phase 1/2 study

Antitumor activity of sorafenib in FLT3-driven leukemic cells

210 A phase 1 study of KTN3379, a human anti-ErbB3 monoclonal antibody in patients with advanced cancers

202 KTN0158, a humanized anti-KIT monoclonal antibody, demonstrates antitumor activity in dogs with mast cell tumors

A conserved family of cellular genes related to the baculovirus iap gene and encoding apoptosis inhibitors

A phase 1 study of OSI-930 in combination with erlotinib in patients with advanced solid tumours

1407P Real-world outcomes in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and tumors with androgen receptor (AR) 878/875 mutations

1803P Phase I/II study of bavdegalutamide, a PROTAC androgen receptor (AR) degrader in metastatic castration-resistant prostate cancer (mCRPC): Radiographic progression-free survival (rPFS) in patients (pts) with AR ligand-binding domain (LBD) mutations

390P Vepdegestrant, a proteolysis targeting chimera (PROTAC) estrogen receptor (ER) degrader, in ER+/human epidermal growth factor receptor 2 (HER2)- advanced breast cancer: Update of dose escalation results from a phase I/II trial

Induction of Nuclear Factor κB by the CD30 Receptor Is Mediated by TRAF1 and TRAF2

Transcriptional repression of the c-fos gene by YY1 is mediated by a direct interaction with ATF/CREB

Tumor necrosis factor receptor-associated factors (TRAFs)--a family of adapter proteins that regulates life and death

CD30 Contains Two Binding Sites with Different Specificities for Members of the Tumor Necrosis Factor Receptor-associated Factor Family of Signal Transducing Proteins

D100 CDX-0159, AN ANTI-KIT MONOCLONAL ANTIBODY, AS A MODULATOR OF MAST CELL-RELATED DISEASES

256TiP TACTIVE-E: Phase Ib study of ARV-471, a PROteolysis TArgeting Chimera (PROTAC) estrogen receptor (ER) degrader, in combination with everolimus in ER+/human epidermal growth factor receptor 2 (HER2)- advanced breast cancer

Translocation of TRAF Proteins Regulates Apoptotic Threshold of Cells

205P VERITAC update: Phase II study of ARV-471, a PROteolysis TArgeting Chimera (PROTAC) estrogen receptor (ER) degrader in ER+/human epidermal growth factor receptor 2 (HER2)- advanced breast cancer

154TiP TACTIVE-N: Open-label, randomized, noncomparative neoadjuvant phase 2 study of ARV-471, a PROteolysis TArgeting Chimera (PROTAC) estrogen receptor (ER) degrader, or anastrozole in postmenopausal women with ER+/human epidermal growth factor receptor 2 (HER2)- localized breast cancer

49 POSTER Analyses of pharmacodynamic (PD) assessments collected during expanded cohorts (EC) of a phase I trial with OSI-930, a multi-targeted oral tyrosine kinase inhibitor (TKI)

Identification of a novel E1A response element in the mouse c-fos promoter

Phase I study of OSI-906, dual tyrosine kinase inhibitor of insulin-like growth factor-1 receptor (IGF-1R) and insulin receptor (IR) in combination with erlotinib (E) in patients with advanced solid tumors

Induction of AP-1 DNA-binding activity and c-fos mRNA by the adenovirus 243R E1A protein and cyclic AMP requires domains necessary for transformation

Phase I study of intermittent dosing of OSI-906, a dual tyrosine kinase inhibitor of insulin-like growth factor-1 receptor (IGF- 1R) and insulin receptor (IR) in patients with advanced solid tumors

A dose escalation (DE), pharmacokinetic (PK), and pharmacodynamic (PD) study of OSI-930 and erlotinib (E) in patients (pts) with advanced solid tumors

First-in-human phase I study exploring three schedules of OSI-027, a novel small molecule TORC1/TORC2 inhibitor, in patients with advanced solid tumors and lymphoma

Suchergebnisse filtern